Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Patient Journey with Amber Spierer, VP Patient Affairs at EQRx

Oct 17, 202226 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Amber Spierer is the VP of Patient Affairs at EQRx, formally head of US Patient Engagement at Novartis. We talk about: Defining the patient journeyWhy understanding this journey is important strategicallyThe difference between viewing someone as a patient and as a personCurrent patient expectations around working with pharmaTacticsThe views expressed here are mine and Amber’s, and don’t reflect those of our employers. Pharma Sessions is hosted by Jonathan Kaskey Follow along on ... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00Hey there. Welcome to Pharmaceutic, a podcast where medical affairs professionals get to learn from each other. I had a great chat with Amber Speyer, Vice President of Patient Affairs at EQRX. We talked about defining the patient journey, why understanding this journey is important strategically, the difference between viewing someone as a patient and as a person, current patient expectations around working with the pharma, and even some tactics. A quick note the views expressed here are mine and Amber's and don't reflect those of our employers.

SPEAKER_00So let's start farm sessions, episode three. Hi Amber. How are you today?

SPEAKER_02I'm good, John.

SPEAKER_00Great. So let's dive right in. Um we're talking with Amber, who's of course vice president of patient affairs at EQRX. And I want to get started by just asking uh patient journey, such a something we all hear about, something that is such a focus for so many companies. How do you define patient journey?

SPEAKER_02Great question, John. You know, I think patient journey is more than what many people think is patient journey. You know, people have so many definitions between, you know, when a patient is diagnosed to the treatment they receive, and then what happens as a result of that. But I like to think of patient journey as more of patient experience or what happens to someone during this different health moment in their life. And so, yes, there is these moments of understanding you have a disease and or a condition, and then what comes from there. It's but it's not just your treatment, or it's not just kind of you know what the disease means to you, it's also how it impacts your life.

SPEAKER_02It's your communication with your healthcare team, it's your communication with your family. So it's many different aspects. So commonly, you know, in different work that I've done and um colleagues of mine have talked about, we talk about patient experience, you know, your patient, the experience of someone living with a disease or a condition.

SPEAKER_00Yeah, and the idea of communication with the team or even with family. I don't know, I just went through a very minor thing, right? I like dropped a tree branch on my foot and I broke a toe, right? Or thought I broke a toe. So I had to go get an x-ray and that had to get faxed to the to my doctor's office. But then he also wanted me to get the CD so I could drive. And this is like the most minor thing that didn't even end up being being anything. And so I'm kind of coordinating, coordinating that and coordinate and answering questions for my family who are asking, like, what happens if this, and it's questions that I forgot about.

SPEAKER_00And it's just struck me like how this the most simple interaction can be so complicated that like if you're dealing with a chronic disease or something important, it's it's gotta be that times a thousand.

SPEAKER_02Yeah, and then add your emotional journey on that. And again, like you said, you could you're talking about a minor example, but if you're going through a life-threatening, you know, you know, diagnosis, and you know, it's not just the tactical way to get through it because there's so many other elements to it. It's how are you feeling? What, you know, what do you need? What kind of support do you need? What kind of support do those around you need? You know, I think also in kind of the world of patient engagement, patient advocacy and patient advocacy, we talk a lot about the individual with the condition or with the disease, but we also have to think about the people around them, the caregivers, what are their needs, what is their journey like?

SPEAKER_02So you started with patient journey, but you could even expand that to you know, not just that individual, but the you know, ecosystem around them that is affected.

SPEAKER_00And so, how much of that support do you think needs to or should come from the pharmacide? And how much of that support is like if you think of pharma's role, kind of them connecting to other resources that that may already exist?

SPEAKER_02I think it's interesting. I think pharma needs to understand what that experience is like because that impacts all different aspects from drug development through, you know, bringing different treatments to patients and you know the physician community. But I think then, you know, at certain points in time, there is a role that pharma can play in providing the right type of services that you know could make sense for or collaborating with an external organization like a patient group or other types of entities to, you know, essentially get the best, you know, service or the best approach for that individual or for people living with a certain condition or disease.

SPEAKER_02So I think it's a mix. I think everyone needs to understand, pharma needs to understand, and then find what are those right points to support that or to implement something like that for a service abuse.

SPEAKER_00What is the strategic importance to a pharmaceutical company to understand, to truly understand the patient journey?

SPEAKER_02I think, you know, it it really, as I was saying, you know, really affects all aspects of the process for a pharmaceutical company. If you're developing a new treatment, you're, you know, thinking about what treatments, what's most important for patients, what's most important for the people with that disease to develop the best treatment for them or the treatment that's next needed, if it's clinical trials, like how do you design a clinical trial in a way that recognizes what someone's life is around in that you know patient population or in that condition, you know, if you're different diseases and conditions, you know, may affect different, you know, age groups and or different genders.

SPEAKER_02And so, how do you think about what someone's lifestyle is like? And then how does that implement into kind of what you're putting in for your clinical trial or designing it and hearing from that person, not through a conduit, is what's really important, you know, like how do they feel, or what would they need to make that job easier? And then as you go along the life cycle, you say, okay, you know, now that that treatment has come to the market, is now available. You know, can people access it? Is it accessible?

SPEAKER_02Like, is there barriers to access, or what's happening at the pharmacy counter, or what's happening in the communications with a physician about, you know, X is diagnosed, you know, someone is diagnosed with the disease, and then they don't even know what to ask for. So there's an empowerment element, and some of that comes through the external community, and that's the important part of the importance of these external partners, like patient organizations. But also there's a role that industry can play as well in helping to guide that and kind of look at what matters most and then what's needed at what points in time.

SPEAKER_00Yeah, it's interesting because a lot of times people talk about you know having a North Star, and sometimes they're talking about the science, right? Or it's a scientific communications platform or something like that. There's some big 60-page PowerPoint document that is the North Star, but it's almost like uh two North stars, or there's the scientific North Star, and then there's the patients who are the people you're actually treating. Um and I'm like, so some of the things that you had mentioned was clinical in clinical trials, right? How to recognize what life is like for a patient.

SPEAKER_00Can you help me understand what you mean by that or how that would impact clinical trials?

SPEAKER_02Sure. Like if you're, you know, trying to run a clinical trial and you're looking for women between 25 and 45 who potentially have a family that they have to take care of, if you make that trial or the protocol hard to you have to show up every day for, you know, it's an extreme example, but every day for a blood test, or you have to have an appointment for three hours, you know, every other week, you know, that can impact how that person will choose to join that trial or continue in that trial, even if, you know, and it's it's hard to imagine, especially with a disease like cancer or another life-threatening condition where, you know, it's easy to say, yes, I need to just be in that trial because this is my hope.

SPEAKER_02But there is living that happens outside that. And it's the thing we talk about from a, you know, to your point, from a scientific perspective of, you know, risk-benefit, you know, like, oh, we've developed the best molecule, you know, a company may say we've developed the best molecule, the best compound that is going to help cure or help treat this disease. Well, the side effects are completely awful, you know, and so more and more we see, and this comes through insights from patients and the patient community, you see that that's not accepted anymore, or that might not be accepted, and that might become, you know, I don't want to be part of this.

SPEAKER_02These are my potential risks, this is my potential inconvenience, and I don't like to use that word, but inconvenience to be in this trial where I can't pick up my children from school. Well, I don't know if I want to do that anymore. And so it all draws back to if you understand a patient or really what I like to say, a person, you know, in the context of their life and being, then how do we design a trial or how do we look at what's needed to reflect that?

SPEAKER_02And, you know, the argument will be you can't design individually, but more and more we have personalized medicine, more and more we have to, you know, be understood or understand that differently.

SPEAKER_00Yeah, and so I like the distinction between a patient and a person because I feel like we always talk about a patient as in like this is the only thing they're going through. Um, but it's not, right? And I remember one program I was involved with um was talking to patients about a clinical trial and they asked some very simple questions, like, would you rather um this was for something that presented birth, so they were not the patients, they were the caregivers of their infants, but it's like, would you rather stay at the hospital or would you rather stay maybe someplace more comfortable near a hospital?

SPEAKER_00And so maybe the optimistic way of looking at it is like if you if you can get to know your population, there are probably some easy wins that you can identify where, you know, to the company, it's no skin off their back if they're putting people up at the hospital or a hotel. But knowing the answer to that actually makes a big difference in recruiting and you know, adherence and all of that other stuff.

SPEAKER_02Exactly, exactly. And, you know, it's it's become more and more challenging. And I think the other element that I would bring up again as part of this is the communication aspect and understanding, you know, I, you know, in my own, you know, personal health experience, like, you know, you know, I was, you know, you know, getting you know treatment at an institution and they just decided when I show up and what I could do and how it could work. And, you know, and you know, the phrase that we would use commonly is they own me now, you know, it's it's to them.

SPEAKER_02And, you know, it's not to discourage or dis diminish the work that they were focused on or the physician was focused on, which is to do the proper protocol and follow the right path. But at the same time, it was kind of a lack of patient acknowledgement, you know, or person acknowledgement, like, oh, like we're just gonna make you sit here for, you know, we we all say it all the time. And even, you know, you go for your annual physical exam and you sit there and wait at the doctor's office for hours because, you know, they're running behind or whatever happens.

SPEAKER_02But you know, take that and it exponentially gets more serious if you're you know under stress or you are facing a serious, you know, condition or you know, illness, and then you're not in control of anything anymore. So it's almost there's an element of communication and empowerment and understanding that I think you know we're continuing to focus on to say this is what's important and this is what's gonna help and drive you know better outcomes for everybody, you know, not just to your point earlier, the scientific outcome, but also the life, you know, feeling.

SPEAKER_00All right. So, how do you gain that understanding?

SPEAKER_02I think that comes through listening, you know, listening to, you know, patients directly, listening to patient advocates who serve the community and understand, you know, and work for, work with their constituents to understand what are the gaps, the challenges, the needs. Um, I think that can come. There's also so many initiatives that these organizations are doing that help to bring forward, you know, what is most important for people with that condition. So, you know, several years ago the FDA, you know, announced the patient-focused drug development initiative, and then that's been evolving over the years.

SPEAKER_02And within that were these, you know, patient voice sessions. And so that's kind of shifted now to the um, with the success of that, it's shifted to the patient community running them, and there's some fabulous voice of the patient reports that start that out, you know, that you listen to you look at and you read and you say, wow, that's the biggest issue that someone is facing or that multiple people are facing. And then from there you, you know, take that and say, well, what does that mean for our strategy? What does that mean for what we need, we as a company or a company would look at?

SPEAKER_02And then, you know, well, then how do I learn more? You know, do I conduct an advisory board? Do I have a focus group? Do I do some more research? Do I use an online platform to gain some insights and perspective? So, you know, for me, it's always you have to start with ins understanding and getting that understanding, and then you drive that through insights and gathering more insights and then folding that into a strategy that's going to help, you know, obviously support the organization and the development, you know, ultimately, what is the goal in as you know, in a company is get the treatments that are needed for patients, you get treatment patients, you know, get treatments out there.

SPEAKER_02And um, but how do you do that in a way that builds upon knowledge and understanding? And that's the same with you bring in the other stakeholder perspectives as well. You know, you have to understand, okay, how easy will this be, you know, for physicians? You know, again, it comes with, you know, I think commonly in industry, the focus has been on the other stakeholders more because of, you know, just the way, especially in the US, that um treatments work. But I think it's shifting a little bit, it's shifted over the years with empowerment of uh you know individual who's saying, okay, well, this is what I need to know, or this is what I want to understand, or this is what's important to me.

SPEAKER_00This episode is sponsored by Structured Meetings. It's a Teams app that turns your own teams incidents into the perfect advisory board platform to save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com. Well, it's also a way to uh question some of the some of your own assumptions, right? So so I was another person that I'd worked with in the past. They had an assumption that their medication it was an injectable and required multiple visits.

SPEAKER_00Um but it was for it was for children, um, and it replaced some like really disgusting oral you know, oral, oral medication. They thought the injection would be a negative and people wouldn't want to do it. But people said, actually, this is preventing, you know, me from having to get my kid to find to drink something awful every single, every single day of our lives. So I'm okay I'm okay with it, right? And that is sort of a it's really interesting because if you're just going by the science, I'm sure I don't actually know the answer to this, but I'm sure there's things that say people have a preference not to be stuck with needles, right?

SPEAKER_00Um, so you could look at that and make some make a reasonable assumption that would just be plain wrong if you don't talk to people and have an understanding.

SPEAKER_02Yeah, that's a big thing that's happened, you know, and I'm not you know up to date fully on where it is now, but when oral cancer therapies came out, that was a huge thing. It was a very much assumed everyone's gonna want to take an oral because it's just taking the pill and that's easy. But some of the insights and perspectives was, you know, you know, patients felt, you know, people going through that process felt that actually like getting you know IV through you is gonna work better or it's going to, it's it's a feeling, you know, as I I just put a pill, like a systematic approach, you know, it was it very different.

SPEAKER_02And I think that required some education and learning and kind of saying, okay, you know, it's the same or it's similar and it's okay. But you know, think about that thing, you know, as innovation occurs, we have to, you know, both think about this is great innovation, but then how is it gonna be, you know, like you said, what is the expectation? How is it perceived? What does that mean? And so, um, but I always go back to that kind of example because I think it's really fascinating. Like, here's you know, instead of sitting in a chair for three hours getting an IV, you know, medicine, you're gonna take a pill and it's gonna be great.

SPEAKER_02But you know, there have been, and like I said, I think it's evolved over time now, but initially there was some pushback and some people still didn't feel comfortable. It's the same. Look, you can talk about telehealth. Telehealth is a whole nother, you know, example there where, you know, depending on the condition and or the disease and kind of what's you know, I don't think every patient feels good about doing a telehealth appointment with their physician. And we've seen some studies on that, that you know, the in-person touch, you know, feels it's more personable, it's you know, you it's connected better.

SPEAKER_02And so I think it's great with technology advancements, innovation advancements, but then how do we understand what that impact will be and use that impact, you know, to kind of help to kind of either educate or adjust as needed, you know, based on what the feedback is on that.

SPEAKER_00It's really interesting. And one of the things you mentioned was a disease being kind of a loss of control for people. And back at a in the day when I was doing a lot of virtual ad boards, we were doing them with doctors and you had to pay them significant sums of money to participate, right? And it was always like a grind to get them to go. And then patients, it was like you open up the spigot and it would just flow out. And to me, I always thought that that was because you're giving them some level of control of this thing that's uh that's weighing heavy on them or a big big part of their life.

SPEAKER_00Um, do you find it's difficult to get patients to open up, or do you find that they're pretty willing to uh to engage?

SPEAKER_02I think they're willing to engage because I think for different reasons. People want to share their story, people want, you know, to see change. You know, there's many different reasons why you know a patient will participate. I think you know, you brought it up, so I have to touch upon it. You know, I think we're also advancing, you know, compensation for patients and patient advocates, the patient community in participating in industry-related activities like that. And I think it's super important. And I'm glad we're finally getting there because, yeah, like there it this is someone's perspective.

SPEAKER_02This is someone using their time, this is someone doing something, you know. So we do have to compensate accordingly, you know, and do it the right way. But I do think there is a, you know, it's the same reason you talk through why do people participate in clinical trials. People do it because they're hoping that it helps them. People are doing it because they want to contribute to science and research. People are doing it to set an example or a model of, you know, here's ways that we can engage or connect better, you know, you know, towards science or innovation. So I think the same with kind of insights and um those types of activities.

SPEAKER_02It's about different people have different motivations, but ultimately I think there is a broader willingness because I think for so long this community wasn't heard or not heard the same way that other stakeholders are heard. And so, how do I share that? And also heard directly, and I think that's another key element is that you know, I can't tell you how you are feeling right now because you're you and I am myself. So, you know, these types of initiatives help for people to express directly and should be tapped directly to share their kind of feeling, their experience, what's going through their head, and compensated appropriately for it.

SPEAKER_00Yeah, absolutely. And there was a voice of the patient article or publication that came out not too long ago about dementia. Um, I think it was maybe last month, um talking to dementia patients. And that was a big part of it, was like nothing about us without us, I think was the term they used or something very similar, um, which it might be a common common saying, but it was the first time I'd heard it. Um I thought it was really interesting, particularly, I mean, even with dementia patients, right?

SPEAKER_00They had a lot to add about what it's like being diagnosed, how what could be done better about their whole their whole journey, about how it doesn't necessarily need to be, you know, some treated the what the way it is, which is basically get your affairs in order and good luck to you. And it's like, no, there's actually a lot of stuff that can happen, but hearing it directly from the patient and then seeing that, or I'm assuming bringing that back to the various people, you know, in the on the science side of the business or on the commercialization side of the business, it's um in that is really it's just seems so important, right?

SPEAKER_00Because that's ultimately like everybody has their day-to-day and they're caught up in the details of what they're doing, but that's ultimately the people that are helped or not helped, depending on how successful companies are.

SPEAKER_02Yeah, no, the the phrase you used is actually a well-known phrase in the advocacy community because it started through them saying, like, stop excluding us, you know, include us. You know, we are the people, you know. So it's why we see more and more integration of you know the patient voice in the steering committee for a clinical trial or a development program. Why you see More adboards that are mixed of patients and physicians, you know, and kind of it's part of the evolution of the space is recognizing that you know you can't just march on without bringing that piece into it, you know.

SPEAKER_02And I think all different stakeholders play different roles, you know, it's not to undermine the professionals, you know, and their you know views, it's more to complement that and also add that perspective directly.

SPEAKER_00Yeah. So what are you most excited about seeing in this space in the near future over the next say three to five years related to how pharma engages with patients?

SPEAKER_02I just, you know, again, I touched upon a lot of it, you know, just how we're kind of helping bring that patient voice even more deeply throughout an organization and more strategically through, you know, an industry and organization. How, you know, with all the good work that you know pharma is doing and other, you know, we're trying to solve for, you know, to kind of help create healthier lives and you know, cure diseases or treat diseases optimally. I think these types of partnerships and you know insights are extremely important to just continue getting everything better, I guess, you know, is what I would say.

SPEAKER_02So I'm just looking forward to the continued advancement of that patient voice through all aspects of the healthcare system. It's not just that kind of one-on-one, it's through the regulatory bodies, it's through the HTA systems, it's through every place that recognize that this voice needs to be heard and is as strong as or equal, you know, strong and equal as the other stakeholders.

SPEAKER_00That's really great. So let's leave it there. Thank you so much for coming today and for talking. I think this is a great conversation and I really appreciate it.

SPEAKER_02Thank you. Thank you for having me, John.

SPEAKER_00Absolutely. This episode is sponsored by Structured Meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and not to brag, but my clients did more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in Teams? And the answer back then was, not really. Teams out of the box is clunky and not fit for purpose.

SPEAKER_00Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own teams instance. So it changes Teams just enough to check all the boxes for what's needed for great ad boards. And also it's super fast and it saves people a ton of money. Visit www.structured meetings.com for more info. All right, well, back to the show.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode